Citigroup Inc. Has $3.42 Million Stake in Nuvation Bio Inc. $NUVB

Citigroup Inc. lowered its holdings in Nuvation Bio Inc. (NYSE:NUVB) by 30.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 922,897 shares of the company’s stock after selling 399,962 shares during the quarter. Citigroup Inc. owned about 0.27% of Nuvation Bio worth $3,415,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in NUVB. Rangeley Capital LLC bought a new position in shares of Nuvation Bio in the second quarter valued at about $25,000. Cetera Investment Advisers bought a new stake in Nuvation Bio during the 2nd quarter worth about $29,000. Captrust Financial Advisors acquired a new stake in Nuvation Bio in the 2nd quarter valued at about $32,000. Atria Investments Inc bought a new position in shares of Nuvation Bio in the second quarter worth about $42,000. Finally, HBK Sorce Advisory LLC acquired a new position in shares of Nuvation Bio during the third quarter worth approximately $42,000. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Stock Down 4.0%

NYSE:NUVB opened at $4.55 on Friday. The company has a quick ratio of 8.39, a current ratio of 6.95 and a debt-to-equity ratio of 0.15. Nuvation Bio Inc. has a 12-month low of $1.54 and a 12-month high of $9.75. The stock’s fifty day simple moving average is $6.35 and its 200-day simple moving average is $5.53. The firm has a market capitalization of $1.56 billion, a P/E ratio of -7.58 and a beta of 1.50.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The firm had revenue of $41.87 million for the quarter, compared to analyst estimates of $36.82 million. Equities research analysts expect that Nuvation Bio Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NUVB. Royal Bank Of Canada increased their price target on shares of Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday. Citizens Jmp set a $10.00 price objective on Nuvation Bio in a research report on Thursday, November 20th. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research note on Tuesday, February 10th. UBS Group cut their price target on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, B. Riley Financial assumed coverage on Nuvation Bio in a research report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvation Bio has a consensus rating of “Moderate Buy” and an average price target of $11.44.

Trending Headlines about Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Nuvation announced a transition to commercial stage with progress on Iptrozi and safusidenib, marking operational progress toward revenue generation and reducing pure clinical-stage risk. Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
• Positive Sentiment: Royal Bank of Canada raised its price target on NUVB to $13, providing another independent valuation boost that can support upside sentiment. Royal Bank Of Canada Boosts Nuvation Bio (NYSE:NUVB) Price Target to $13.00
• Positive Sentiment: H.C. Wainwright maintained a Buy rating and a $17 target on NUVB, signaling continued analyst conviction despite model revisions — a supportive counterweight for investor sentiment. H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)
• Neutral Sentiment: Industry coverage flagged commercialization and partner execution risks for taletrectinib — useful context for evaluating upside but not a direct new corporate action. Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
• Negative Sentiment: H.C. Wainwright reduced EPS estimates across Q1–Q4 and cut FY2026 EPS forecasts (e.g., FY now -$0.44 vs prior -$0.35). Earnings downgrades signal weaker near-term profitability expectations and likely contributed to downward price pressure.
• Negative Sentiment: UBS lowered its expectations for NUVB, adding to sell-side skepticism that can amplify volatility and limit near-term upside. UBS Group Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price
• Negative Sentiment: A shareholder law firm (Johnson Fistel) announced an investigation into potential securities-law claims involving Nuvation and its officers — a legal probe that increases headline risk and can weigh on investor confidence. Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.